Uronormin-F granules for the preparation of oral solution 3g, no. 1 package

• Treatment of infectious and inflammatory diseases (caused by microorganisms sensitive to the drug) of the lower urinary tract, incl.

• acute bacterial cystitis,

• exacerbation of chronic recurrent bacterial cystitis,

• acute bacterial uravesical syndrome,

• bacterial nonspecific urethritis,

• asymptomatic massive bacteriuria (during pregnancy),

• postoperative urinary tract infection.

• Prevention of urinary tract infection during surgery and transurethral diagnostic examinations.

Inside.

The powder is dissolved in 1/2 glass of water (50-75 ml) or another drink, stirred until completely dissolved, taken immediately after dissolution. Uronormin-F is used once a day by mouth on an empty stomach 1 hour before or 2-3 hours after a meal, preferably before bedtime, having previously emptied the bladder. Adults and children from 12 to 18 years old: 1 packet (3 g) once a day, once.

In order to prevent infection of the urinary tract during surgery, transurethral diagnostic procedures, fosfomycin is taken 2 times, 3 g each: 3 hours before the intervention and 24 hours after the intervention.

Powder for preparation of oral solution is granular, white or almost white in color, with a characteristic fruity odor.

1 pack.

fosfomycin trometamol 5.631 g

which corresponds to the content of fosfomycin 3 g

Excipients: sucrose - 2.213 g, tangerine flavor - 0.07 g, orange flavor - 0.07 g, sodium saccharinate - 0.016 g.

• Severe renal failure (CC <10 ml / min),

• hypersensitivity to fosfomycin.

• children under 12 years old

pharmachologic effect

Broad-spectrum antibiotic. The mechanism of action is associated with the suppression of the first stage of peptidoglycan synthesis of the bacterial cell wall. Being a structural analogue of phosphoenol pyruvate, it enters into a competitive interaction with the enzyme N-acetyl-glucosamino-3-o-enolpyruvyl transferase, as a result of which a specific, selective and irreversible inhibition of this enzyme occurs.

Active against most gram-negative bacteria: Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae; gram-positive bacteria: Staphylococcus spp. (including Staphylococcus aureus, Staphylococcus epidermidis), Streptococcus spp. (including Enterococcus faecalis).

Pharmacokinetics

The absorption is 60%; binding to plasma proteins - 10%. Cmax when taken orally at a dose of 50 mg / kg - 32 ?g / ml; with intravenous administration at a dose of 20 mg / kg - 130 ?g / kg; T1 / 2 - 2.2 hours. Penetrates quickly and is well distributed in tissues. 90% is excreted by the kidneys with the creation of high concentrations in the urine.

Side effect

From the digestive system: infrequently - dyspeptic symptoms, incl. nausea, diarrhea; rarely - abdominal pain, vomiting.

Allergic reactions: rarely - rash, urticaria, itching.

From the nervous system: infrequently - headache, dizziness; rarely - paresthesia.

From the side of the cardiovascular system: very rarely - tachycardia.

Others: rarely - fatigue, aplastic anemia.

Application during pregnancy and lactation

During pregnancy, use is possible only if the expected benefit of therapy to the mother outweighs the potential risk to the fetus.

If necessary, the use of fosfomycin during lactation, breastfeeding should be discontinued.

Application in children

In infants, the use of fosfomycin is possible only in cases of extreme necessity under the supervision of a physician.

special instructions

Use with caution in patients with liver disease, impaired renal function (CC> 12 ml / min), in elderly patients.

In infants, the use of fosfomycin is possible only in cases of extreme necessity under the supervision of a physician.